R I Merz1, J Deakin, M R Hawthorne. 1. ENT Department, James Cook University Hospital, Middlesbrough, UK. merzr@uhbs.ch
Abstract
OBJECTIVE: To develop and validate a disease-specific instrument to measure health-related quality of life in patients with oromandibular dystonia. DESIGN: Prospective, cross-sectional observational study. SETTING: Tertiary referral clinic, North East England, UK. METHODS: The Oromandibular Dystonia Questionnaire (OMDQ-25) was evaluated in a group of 30 patients for psychometric properties, including its sensitivity to change after Botulinum Toxin A treatment. Comparison to a generic instrument was enabled using the Glasgow Health Scale Inventory and the Glasgow Benefit Inventory (GBI). RESULTS: Item generation passed tests for scaling assumptions. Reliability was proven (Cronbach's α > 0.78; test-retest > 0.9) and validity supported with both convergent validity and discriminant validity. Sensitivity to change after Botulinum Toxin A treatment was established for all subscales (P ≤ 0.005), and in comparison with the GBI, all subscales showed large effect sizes. CONCLUSION: The Oromandibular Dystonia Questionnaire (OMDQ-25) is the first reliable and valid instrument to measure health-related quality of life in patients with oromandibular dystonia.
OBJECTIVE: To develop and validate a disease-specific instrument to measure health-related quality of life in patients with oromandibular dystonia. DESIGN: Prospective, cross-sectional observational study. SETTING: Tertiary referral clinic, North East England, UK. METHODS: The Oromandibular Dystonia Questionnaire (OMDQ-25) was evaluated in a group of 30 patients for psychometric properties, including its sensitivity to change after Botulinum Toxin A treatment. Comparison to a generic instrument was enabled using the Glasgow Health Scale Inventory and the Glasgow Benefit Inventory (GBI). RESULTS: Item generation passed tests for scaling assumptions. Reliability was proven (Cronbach's α > 0.78; test-retest > 0.9) and validity supported with both convergent validity and discriminant validity. Sensitivity to change after Botulinum Toxin A treatment was established for all subscales (P ≤ 0.005), and in comparison with the GBI, all subscales showed large effect sizes. CONCLUSION: The Oromandibular Dystonia Questionnaire (OMDQ-25) is the first reliable and valid instrument to measure health-related quality of life in patients with oromandibular dystonia.
Authors: Laura Nastasi; Giovanni Mostile; Alessandra Nicoletti; Mario Zappia; Ester Reggio; Santiago Catania Journal: J Neurol Date: 2016-06-08 Impact factor: 4.849
Authors: Laura M Scorr; Michael R Silver; John Hanfelt; Elaine Sperin; Alan Freeman; H A Jinnah; Stewart A Factor Journal: Neurotherapeutics Date: 2018-04 Impact factor: 7.620
Authors: Laura M Scorr; Stewart A Factor; Sahyli Perez Parra; Rachel Kaye; Randal C Paniello; Scott A Norris; Joel S Perlmutter; Tobias Bäumer; Tatiana Usnich; Brian D Berman; Marie Mailly; Emmanuel Roze; Marie Vidailhet; Joseph Jankovic; Mark S LeDoux; Richard Barbano; Florence C F Chang; Victor S C Fung; Sarah Pirio Richardson; Andrew Blitzer; H A Jinnah Journal: Front Neurol Date: 2021-09-16 Impact factor: 4.003
Authors: Linda Slaim; Myriam Cohen; Patrick Klap; Marie Vidailhet; Alain Perrin; Daniel Brasnu; Denis Ayache; Marie Mailly Journal: J Mov Disord Date: 2018-05-30